Cardiovascular

Webinar: New NZ CVD primary care 2018 guidelines

WEBINAR 20 March 2018: Register to hear Associate Professor Gerry Devlin and Dr Fraser Hamilton on the new Consensus Statement on Cardiovascular Disease Risk Assessment and Management for Primary Care.

High dose vitamin D supplementation does not prevent CVD

Gem: To date, randomized clinical trials of vitamin D supplementation have not found an effect, possibly because of using too low a dose of vitamin D.

Webinar: Statins; who, when, where and why

In this webinar Dr Tony Scott, cardiologist talked about the use of statins in primary care and dealt with questions such as 'are all statins equal?' and 'how do you prescribe statins and maintain medication compliance?" 

Also covered was how to approach discussions around the size of the benefit to enable patients to be fully informed (re taking statins) and how to discuss potential harms eg., dementia, diabetes, fatigue and muscle aches.

 

Spironolactone; effective but regular serum potassium checks recommended forever

Spironolactone is effective for NYHA class III and IV heart failure and hypertension (4th or 5th line) but can be a difficult drug to use.

Beta-blockers no longer first line for simple hypertension

Initiating treatment of hypertension with beta-blockers leads to modest CVD reductions and little or no effects on mortality (atenolol mainly studied).

Association between gout and high intakes of fructose – consider reducing it

This meta-analysis of prospective cohort studies investigated the association of fructose consumption with incident gout and hyperuricemia.

New drug treatment for heart failure

PODCAST: Professor Rob Doughty talks about a new combination medicine to New Zealand for the management of congestive heart failure - ‘Entresto’ Sacubitril/ Valsarten.

Pages

Subscribe to Cardiovascular